SynthesisBMC infectious diseases2025
Genital mycoplasma infections: a hidden factor in cervical cancer progression? A systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MUREAPLEXE: A multiplex recombinant antigen-based ELISA expanding the serological detection spectrum of urogenital mycoplasmas.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Associations of non-HPV genital pathogen detection with HPV positivity and cervical findings in women undergoing screening in Xinjiang, China: a retrospective cross-sectional study.Frontiers in medicine · 2026Article
- Role of Gut Microbiome in Oncogenesis and Oncotherapies.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExploring the role of the microbiome, specifically genital mycoplasmas, in cervical cancer (CC) offers insights into tumorigenesis, potential therapeutic targets and personalized treatment strategies. Although mycoplasmas are generally identified as commensals, their contributions to gynecological cancers, mainly CC, is increasingly recognized. This study investigates the association between CC and genital mycoplasma infections, highlighting the interactions with human papillomavirus (HPV) and their impact on cellular and immune mechanisms.
methodsWe conducted a systematic review and meta-analysis of databases through June 2024. Association strength was determined using pooled odds ratios (ORs) with 95% confidence intervals (CIs). Six case-control studies involving 319 cervical cancer patients and 447 controls were included.
resultsPooled results showed that genital mycoplasmas were associated with a significantly increased risk of CC (OR = 1.64; 95% CI 1.25-2.14). The species-specific analysis demonstrated that Ureaplasma urealyticum was linked with a high risk of CC (OR = 1.81, 95% CI 1.31-2.51), while no significant association was seen for Ureaplasma parvum. HPV-positive subjects co-infected with genital mycoplasmas had a markedly increased risk of CC (OR = 3.13, 95% CI 2.04-4.79), highlighting potential synergistic effects in tumor progression.
conclusionMycoplasmas, particularly U. urealyticum, constitute co-factors in the development of CC, likely by influencing HPV persistence and immune evasion. Systemic screening coupled with targeted treatment of genital mycoplasmas in high-risk populations is thus warranted for CC prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.